TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT04165070: KEYMAKER-U01 Substudy 01A: A Phase 1/2, Umbrella Study With Rolling Arms of Investigational Agents With Pembrolizumab With or Without Chemotherapy in Treatment-Naive Participants With Stage IV Non-small Cell Lung Cancer

Sponsor: Merck Sharp & Dohme LLC · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 450 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$8,325,240

Rescue Site Savings

+$5,497,800

Unlock Full NCT04165070 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT04165070 Rescue Dossier →